{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:57:17Z","timestamp":1790081837362,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Bupropion, an antidepressant inhibiting the reuptake of dopamine and noradrenaline, should be useful to treat depressive symptoms in patients with Parkinson\u2019s disease (PD). Limited and conflicting literature data questioned its effectiveness and safety in depressed PD patients and extended its use to other neuropsychiatric symptoms associated with this disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>The databases PubMed, Embase, Web of Sciences, Cochrane Library, and the grey literature were searched. Following a scoping review methodology, articles focusing on Bupropion uses in PD patients who manifested depressive or other neuropsychiatric alterations were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three articles were selected, including 7 original articles, 3 systematic reviews or meta-analyses, 11 case reports, 1 clinical guideline, and 1 expert opinion. Bupropion showed considerable effectiveness in reducing depressive symptoms, particularly in relation to apathy. Solitary findings showed a restorative effect on compulsive behaviour secondary to treatment with dopamine as well as on anxiety symptoms. The effect on motor symptoms remains controversial. The safety profile of this medication seems positive, but additional precautions should be used in subjects with psychotic symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The available literature lacks good evidence to support the use of Bupropion in PD patients presenting depressive symptoms. Further investigations are needed to extend and confirm reported findings and to produce accurate clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-022-02668-4","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:51:51Z","timestamp":1651711911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clinical uses of Bupropion in patients with Parkinson\u2019s disease and comorbid depressive or neuropsychiatric symptoms: a scoping review"],"prefix":"10.1186","volume":"22","author":[{"given":"Matteo","family":"Vismara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Benatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Cova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Monfrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Di Fonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Fetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina A.","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Priori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Dell\u2019Osso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"2668_CR1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.23732","volume":"26","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson\u2019s disease. Mov Disord. 2011;26:1049\u201355.","journal-title":"Mov Disord"},{"key":"2668_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jns.2016.12.060","volume":"373","author":"R Balestrino","year":"2017","unstructured":"Balestrino R, Martinez-Martin P. Neuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson\u2019s disease. J Neurol Sci. 2017;373:173\u20138.","journal-title":"J Neurol Sci"},{"key":"2668_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2147\/NDT.S130997","volume":"13","author":"S Szatmari","year":"2017","unstructured":"Szatmari S, Min-Woo Illigens B, Siepmann T, Pinter A, Takats A, Bereczki D. Neuropsychiatric symptoms in untreated Parkinson&rsquo;s disease. Neuropsychiatr Dis Treat. 2017;13:815\u201326.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2668_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3233\/JAD-191333","volume":"75","author":"M Vismara","year":"2020","unstructured":"Vismara M, Cirnigliaro G, Piccoli E, Giorgetti F, Molteni L, Cremaschi L, et al. Crossing borders between frontotemporal dementia and psychiatric disorders: an updated overview. J Alzheimers Dis. 2020;75:661\u201373.","journal-title":"J Alzheimers Dis"},{"key":"2668_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00406-011-0196-4","volume":"261","author":"AC Altamura","year":"2011","unstructured":"Altamura AC, Serati M, Albano A, Paoli RA, Glick ID, Dell\u2019Osso B. An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. Eur Arch Psychiatry Clin Neurosci. 2011;261:489\u2013508.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2668_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jama.281.4.376","volume":"281","author":"JL Cummings","year":"1999","unstructured":"Cummings JL. Understanding Parkinson Disease. JAMA. 1999;281:376.","journal-title":"JAMA."},{"key":"2668_CR7","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/mds.22589","volume":"24","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson\u2019s disease. Mov Disord. 2009;24:2175\u201386.","journal-title":"Mov Disord"},{"key":"2668_CR8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/14737175.7.6.711","volume":"7","author":"LL Borek","year":"2007","unstructured":"Borek LL, Chou KL, Friedman JH. Management of the behavioral aspects of Parkinson\u2019s disease. Expert Rev Neurother. 2007;7:711\u201325.","journal-title":"Expert Rev Neurother"},{"key":"2668_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1468-1331.2008.02058.x","volume":"15","author":"MR Lemke","year":"2008","unstructured":"Lemke MR. Depressive symptoms in Parkinson\u2019s disease. Eur J Neurol. 2008;15:21\u20135.","journal-title":"Eur J Neurol"},{"key":"2668_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","volume":"8","author":"L Shulman","year":"2002","unstructured":"Shulman L, Taback R, Rabinstein A, Weiner W. Non-recognition of depression and other non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2002;8:193\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"2668_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/psyg.12078","volume":"15","author":"A Dyduch","year":"2015","unstructured":"Dyduch A, Za\u0142uska M. Depression in Parkinson\u2019s disease: the effectiveness and risk of pharmacotherapy. Clinical review. Psychogeriatrics. 2015;15:147\u201353.","journal-title":"Psychogeriatrics"},{"key":"2668_CR12","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/14656566.2019.1612877","volume":"20","author":"M Ryan","year":"2019","unstructured":"Ryan M, Eatmon CV, Slevin JT. Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother. 2019;20:1351\u201363.","journal-title":"Expert Opin Pharmacother"},{"key":"2668_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.mehy.2010.07.024","volume":"75","author":"S Raskin","year":"2010","unstructured":"Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson\u2019s disease and it\u2019s various treatments. Med Hypotheses. 2010;75:544\u20136.","journal-title":"Med Hypotheses"},{"key":"2668_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.clinthera.2005.11.011","volume":"27","author":"JW Jefferson","year":"2005","unstructured":"Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther. 2005;27:1685\u201395.","journal-title":"Clin Ther"},{"key":"2668_CR15","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1093\/brain\/awh445","volume":"128","author":"P Remy","year":"2005","unstructured":"Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson\u2019s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314\u201322.","journal-title":"Brain."},{"key":"2668_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/acn3.707","volume":"6","author":"GR Uhl","year":"2019","unstructured":"Uhl GR. Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson\u2019s disease and therapeutic opportunities. Ann Clin Transl Neurol. 2019;6:406\u201315.","journal-title":"Ann Clin Transl Neurol"},{"key":"2668_CR17","first-page":"2157","volume":"144","author":"AF Leentjens","year":"2000","unstructured":"Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion. Ned Tijdschr Geneeskd. 2000;144:2157\u20139.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2668_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0885-3924(97)00176-0","volume":"14","author":"WM Stein","year":"1997","unstructured":"Stein WM, Read S. Chronic pain in the setting of Parkinson\u2019s disease and depression. J Pain Symptom Manag. 1997;14:255\u20138.","journal-title":"J Pain Symptom Manag"},{"key":"2668_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1017\/S1041610210001687","volume":"23","author":"M Za\u0142uska","year":"2011","unstructured":"Za\u0142uska M, Dyduch A. Bupropion in the treatment of depression in Parkinson\u2019s disease. Int Psychogeriatr. 2011;23:325\u20137.","journal-title":"Int Psychogeriatr"},{"key":"2668_CR20","unstructured":"NICE. Depression in adults: recognition and management. National Institute for Health and Care Excellence. 2009. https:\/\/www.nice.org.uk\/guidance\/cg90."},{"key":"2668_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1212\/WNL.34.8.1092","volume":"34","author":"CG Goetz","year":"1984","unstructured":"Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson\u2019s disease. Neurology. 1984;34:1092.","journal-title":"Neurology."},{"key":"2668_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/070674370104600615","volume":"46","author":"L Jerome","year":"2001","unstructured":"Jerome L. Bupropion and Drug-Induced Parkinsonism. Can J Psychiatr. 2001;46:560\u20131.","journal-title":"Can J Psychiatr"},{"key":"2668_CR23","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/mds.21425","volume":"22","author":"F Grandas","year":"2007","unstructured":"Grandas F, L\u00f3pez-Manzanares L. Bupropion-induced parkinsonism. Mov Disord. 2007;22:1830\u20131.","journal-title":"Mov Disord"},{"key":"2668_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/AOMD.AOMD_35_19","volume":"3","author":"J Pitton Rissardo","year":"2020","unstructured":"Pitton Rissardo J, Fornari CA. Bupropion-associated movement disorders: A systematic review. Ann Mov Disord. 2020;3:86.","journal-title":"Ann Mov Disord"},{"key":"2668_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s11910-996-0041-8","volume":"6","author":"DB Rye","year":"2006","unstructured":"Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2006;6:169\u201376.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2668_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11910-009-0026-5","volume":"9","author":"R Monderer","year":"2009","unstructured":"Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson\u2019s disease. Curr Neurol Neurosci Rep. 2009;9:173\u201380.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2668_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","volume":"5","author":"D Levac","year":"2010","unstructured":"Levac D, Colquhoun H, O\u2019Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69.","journal-title":"Implement Sci"},{"key":"2668_CR28","first-page":"19","volume":"8","author":"OH Arskey","year":"2007","unstructured":"Arskey OH. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2007;8:19\u201332.","journal-title":"Int J Soc Res Methodol"},{"key":"2668_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/ggi.13237","volume":"18","author":"BJ Ahn","year":"2018","unstructured":"Ahn BJ, Kwon KY. Elderly woman presenting with unusual propriospinal myoclonus triggered by drug-induced nausea and vomiting. Geriatr Gerontol Int. 2018;18:504\u20135.","journal-title":"Geriatr Gerontol Int"},{"key":"2668_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/mds.23395","volume":"26","author":"D Benincasa","year":"2011","unstructured":"Benincasa D, Pellicano C, Fanciulli A, Pontieri FE. Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson\u2019s disease. Mov Disord. 2011;26:355\u20137.","journal-title":"Mov Disord"},{"key":"2668_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/0891988707301866","volume":"20","author":"P Chen","year":"2007","unstructured":"Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson\u2019s disease and depression: Analysis of a national sample. J Geriatr Psychiatry Neurol. 2007;20:161\u20135.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"2668_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2710.2008.00952.x","volume":"33","author":"S Gebhardt","year":"2008","unstructured":"Gebhardt S, R\u00f6ttgers H, B\u00e4cker A, Schu U, Krieg J-C. Treatment of panic disorder with bupropion in a patient with Parkinson\u2019s disease. J Clin Pharm Ther. 2008;33:575\u20137.","journal-title":"J Clin Pharm Ther"},{"key":"2668_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/WNF.0000000000000359","volume":"42","author":"EA Honkanen","year":"2019","unstructured":"Honkanen EA, Kemppainen N, Noponen T, Sepp\u00e4nen M, Joutsa J, Kaasinen V. Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism. Clin Neuropharmacol. 2019;42:181\u20133.","journal-title":"Clin Neuropharmacol"},{"key":"2668_CR34","doi-asserted-by":"publisher","first-page":"681.e11","DOI":"10.1016\/j.genhosppsych.2013.04.020","volume":"35","author":"N Kate","year":"2013","unstructured":"Kate N, Grover S, Kumar S, Modi M. Bupropion-induced hyponatremia. Gen Hosp Psychiatry. 2013;35:681.e11\u20132.","journal-title":"Gen Hosp Psychiatry"},{"key":"2668_CR35","first-page":"39","volume":"9","author":"N Kaur","year":"2012","unstructured":"Kaur N, Madan R, Sharma A. Successful use of rasagiline in combination with two antidepressants: A case report. Innov Clin Neurosci. 2012;9:39\u201341.","journal-title":"Innov Clin Neurosci"},{"key":"2668_CR36","doi-asserted-by":"crossref","unstructured":"Kim W, Kim H, Oh S, Kim O, Lee M. Effects of bupropion on depression of Parkinson\u2019s disease: Open-label 12-week trial in Korea - Poster 4-021. Mov Disord. 2009:S241\u20131.","DOI":"10.1016\/j.jalz.2010.08.081"},{"key":"2668_CR37","unstructured":"Kim W, Oh S, Kim H, Kim O. Bupropion on freezing of gait in Parkinson\u2019s Disease - Poster 2.270. Parkinsonism Relat Disord. 2012:S81\u2013159."},{"key":"2668_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1590\/S0004-282X2006000600026","volume":"64","author":"A Kummer","year":"2006","unstructured":"Kummer A, Maia DP, Salgado JV, Cardoso FEC, Teixeira AL. Dopamine dysregulation syndrome in Parkinson\u2019s disease: case report. Arq Neuropsiquiatr. 2006;64:1019\u201322.","journal-title":"Arq Neuropsiquiatr"},{"key":"2668_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3109\/10401239709147768","volume":"9","author":"JL Ritter","year":"1997","unstructured":"Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997;9:7\u201313.","journal-title":"Ann Clin Psychiatry"},{"key":"2668_CR40","unstructured":"Trivedi A, Srivastava T, Batra D. Comparative study of efficacy for Bupropion vs Sertraline (SSRI) in depression with Parkinson\u2019s disease. Yokohama, Japan. XII World Congress of Psychiatry, Aug 24\u20139. 2002."},{"key":"2668_CR41","doi-asserted-by":"crossref","unstructured":"Vasile D, Macovei RA, Vasiliu O. Efficacy and tolerability of bupropion in major depressive disorder associated with Parkinson\u2019s disease Poster 2.b.007. Eur Neuropsychopharmacol. 2013:S322\u20133.","DOI":"10.1016\/S0924-977X(13)70506-6"},{"key":"2668_CR42","doi-asserted-by":"publisher","first-page":"241","DOI":"10.14802\/jmd.20046","volume":"13","author":"M Vegda","year":"2020","unstructured":"Vegda M, Panda S. Bupropion-Induced Dystonia in a Patient with Parkinson\u2019s Disease. J Mov Disord. 2020;13:241\u20133.","journal-title":"J Mov Disord"},{"key":"2668_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6621991","volume":"2021","author":"L Ag\u00fcera-Ortiz","year":"2021","unstructured":"Ag\u00fcera-Ortiz L, Garc\u00eda-Ramos R, Grandas P\u00e9rez FJ, L\u00f3pez-\u00c1lvarez J, Montes Rodr\u00edguez JM, Olazar\u00e1n Rodr\u00edguez FJ, et al. Focus on Depression in Parkinson\u2019s Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics. Parkinsons Dis. 2021;2021:1\u201311.","journal-title":"Parkinsons Dis"},{"key":"2668_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/gps.4834","volume":"33","author":"KA Mills","year":"2018","unstructured":"Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM. Efficacy and tolerability of antidepressants in Parkinson\u2019s disease: A systematic review and network meta-analysis. Int J Geriatr Psychiatry. 2018;33:642\u201351.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2668_CR45","unstructured":"Paumier KL, Siderowf AD, Auinger P, Oakes D, Espay AJ, Revilla FJ, et al. Antidepressant treatment may have disease modifying-effects in early Parkinson\u2019s disease: A patient-level meta-analysis - Poster. Mov Disord. 2010:III."},{"key":"2668_CR46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.nrl.2016.02.002","volume":"33","author":"E Pe\u00f1a","year":"2018","unstructured":"Pe\u00f1a E, Mata M, L\u00f3pez-Manzanares L, Kurtis M, Eimil M, Mart\u00ednez-Castrillo JC, et al. Antidepresivos en la enfermedad de Parkinson. Recomendaciones del grupo de trastornos del movimiento de la Asociaci\u00f3n Madrile\u00f1a de Neurolog\u00eda. Neurolog\u00eda. 2018;33:395\u2013402.","journal-title":"Neurolog\u00eda"},{"key":"2668_CR47","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/mds.20555","volume":"20","author":"D Weintraub","year":"2005","unstructured":"Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, et al. Antidepressant studies in Parkinson\u2019s disease: A review and meta-analysis. Mov Disord. 2005;20:1161\u20139.","journal-title":"Mov Disord"},{"key":"2668_CR48","doi-asserted-by":"crossref","unstructured":"Mlinari\u0107 A, Horvat M, \u0160upak Smol\u010di\u0107 V. Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Med (Zagreb). 2017;27(3):030201.","DOI":"10.11613\/BM.2017.030201"},{"key":"2668_CR49","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp.73.6.636","volume":"73","author":"GC Pluck","year":"2002","unstructured":"Pluck GC, Brown RG. Apathy in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;73:636\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2668_CR50","first-page":"35","volume-title":"Parkinson\u2019s Disease [CG35]: National clinical guideline for diagnosis and management in primary and secondary care","author":"NICE","year":"2006","unstructured":"NICE. Parkinson\u2019s Disease [CG35]: National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2006. p. 35."},{"key":"2668_CR51","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","volume":"51","author":"R Costa","year":"2019","unstructured":"Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51:293\u2013313.","journal-title":"Drug Metab Rev"},{"key":"2668_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"2668_CR53","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1212\/WNL.0000000000000863","volume":"83","author":"N Kitagawa","year":"2014","unstructured":"Kitagawa N, Takeuchi A. Memantine-induced myoclonus. Neurology. 2014;83:1387.","journal-title":"Neurology."},{"key":"2668_CR54","unstructured":"Huecker MR, Smiley A, Saadabadi A. Bupropion. 2021. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022."},{"key":"2668_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.clinthera.2008.05.010","volume":"30","author":"GI Robles","year":"2008","unstructured":"Robles GI, Singh-Franco D, Ghin HL. A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations. Clin Ther. 2008;30:800\u201312.","journal-title":"Clin Ther"},{"key":"2668_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4088\/PCC.v06n0403","volume":"06","author":"SM Stahl","year":"2004","unstructured":"Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;06:159\u201366.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2668_CR57","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.genhosppsych.2011.07.001","volume":"33","author":"S Kumar","year":"2011","unstructured":"Kumar S, Kodela S, Detweiler JG, Kim KY, Detweiler MB. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature. Gen Hosp Psychiatry. 2011;33:612\u20137.","journal-title":"Gen Hosp Psychiatry"},{"key":"2668_CR58","unstructured":"eHealth Me. Wellbutrin and Hyponatraemia - a phase IV clinical study of FDA data. 2021. http:\/\/www.ehealthme.com\/ds\/wellbutrin\/hyponatraemia."},{"key":"2668_CR59","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328:1490\u20134.","journal-title":"Br Med J"},{"key":"2668_CR60","unstructured":"Oxford Centre for Evidence-Based Medicine. OCEBM Levels of Evidence Working Group. \u201cThe Oxford Levels of Evidence 2\u201d. 2011. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02668-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T01:19:53Z","timestamp":1651713593000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02668-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02668-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"2 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Vismara is the Principal Investigator of the study \u201cBupropion for depression in Parkinson\u2019s disease: clinical and epigenetic correlates\u201d sponsored by \u201cAldo Ravelli\u201d Center for Neurotechnology and Brain Therapeutic, University of Milan, Milan.Prof. Dell\u2019Osso has received Grant\/Research Support from LivaNova, Inc., Angelini and Lundbeck and Lecture Honoraria from Angelini, FB Health and Lundbeck.Prof. Priori, Dr. Nicolini, Dr. Benatti, Dr. Cova, Dr. Di Fonzo, Dr. Monfrini, Dr. Fetoni, and Dr. Vigan\u00f2 report no financial relationships with commercial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}